Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
24-valent pneumococcal conjugate vaccine (Shandong Kunli Biopharmaceutical)
- Development stage
- Unknown
- Lead developer
- Shandong Kunli Biopharmaceutical
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The 24-valent pneumococcal conjugate vaccine (PCV24) is a multivalent biologic developed by Shandong Kunli Biopharmaceutical for the prevention of pneumococcal diseases, including pneumonia and invasive infections caused by *Streptococcus pneumoniae*. This vaccine is designed to provide broader protection than earlier generation vaccines (such as PCV13 or PCV15) by targeting 24 distinct serotypes of the bacterium. The mechanism involves conjugating capsular polysaccharides from these serotypes to a carrier protein, which enhances the immune response by recruiting T-cell help, thereby inducing long-term immunological memory. This approach is particularly effective in vulnerable populations such as infants and the elderly. The vaccine is currently in Phase 1/2 clinical development in China.
- Other names
- 24价肺炎结合疫苗24-valent Pneumococcal Conjugate Vaccine
02
Targets
BCR (Immunoglobulin G B Cell Receptor)CD4+ T cell receptor recognizing carrier protein-derived peptides presented on MHC class IICPS (Streptococcus pneumoniae capsular polysaccharide)
Beyond the preview
Go deeper on 24-valent pneumococcal conjugate vaccine (Shandong Kunli Biopharmaceutical).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 24-valent pneumococcal conjugate vaccine (Shandong Kunli Biopharmaceutical).